Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ciara Rubenstein

Nurse Practitioner New Braunfels, TX Nurse Practitioner

NPI 1891264032 CMS profile 10975966

213 Hunters Vlg, New Braunfels, TX 78132

Open in the dashboard

General payments

$4,967

139 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ciara Rubenstein of New Braunfels, TX is reported in the CMS Open Payments database as having received $4,967 across 139 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,455 39
2024 General $1,213 49
2023 General $1,103 36
2022 General $1,197 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ciara Rubenstein
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Ciara Rubenstein were reported at $1,455. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Ciara Rubenstein Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $1,197 $152 $48–$470 $149
2023 $1,103 $166 $54–$529 $160
2024 $1,213 $173 $55–$556 $164
2025 $1,455 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Nevro Corp. $1,565 52 payments
  2. Spinal Simplicity, LLC $1,250 24 payments
  3. Globus Medical, Inc. $1,178 32 payments
  4. SI-BONE, Inc. $213 3 payments
  5. Medtronic, Inc. $185 12 payments
  6. Boston Scientific Corporation $171 2 payments
  7. Relievant Medsystems, Inc. $116 3 payments
  8. Painteq LLC $94 1 payment
  9. Averitas Pharma Inc. $63 3 payments
  10. Nalu Medical, Inc. $54 3 payments
  11. Other $78 4 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,253 135 payments
  2. Travel and Lodging $714 4 payments
Products named General payments · program years 2022–2025
  1. Senza Spinal Cord Stimulator $1,565 52 payments
  2. HA MINUTEMAN G3-R $1,250 24 payments
  3. Senza Spinal Cord Stimulator $991 27 payments
  4. Vyrsa V1 $170 3 payments
  5. VANTA ADAPTIVESTIM $145 8 payments
  6. Intracept Intracept Access Instruments - Additional VB (Gen 3)_NMOD $122 1 payment
  7. Intracept Pain $116 3 payments
  8. Intracept Pain $116 3 payments
  9. Intracept Pain $116 3 payments
  10. Intracept Pain $116 3 payments
  11. Other $374 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,230

Median for Nurse Practitioner: 389

Drug cost

$115,677

Median for Nurse Practitioner: $21,885

Branded share of claims

13.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 54 $46,227
Buprenorphine Generic 98 $32,372
Pregabalin Generic 236 $5,113
Lidocaine Generic 51 $4,971
Acetaminophen-Codeine Acetaminophen With Codeine Brand 191 $4,428
Gabapentin Generic 320 $4,093
Buprenorphine Hcl Generic 71 $3,233
Tramadol Hcl Er Tramadol Hcl Brand 48 $2,821
Tramadol Hcl Generic 342 $2,717
Tizanidine Hcl Generic 191 $1,942

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$76,684

Medicare's payments for the services billed

Medicare patients

322

Average age 72

Services billed

1,355

196 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Ischemic heart disease 34%
Depression 34%
Chronic kidney disease 27%
Osteoporosis 18%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record